Thermofisher 2022 2nd Qtr. results-Strong results

Thermo Fisher Scientific Reports Second Quarter 2022 ResultsJuly 28, 2022WALTHAM, Mass.–(BUSINESS WIRE)– Thermo Fisher Scientific Inc. (NYSE: TMO), the world leader in serving science, today reported its financial results for the second quarter ended July 2, 2022.Second Quarter 2022 HighlightsSecond quarter revenue was $10.97 billion.Second quarter GAAP diluted earnings per share (EPS) was $4.22.Second quarter adjusted EPS was $5.51.Delivered very strong financial results in the second quarter, with 13% Core organic revenue growth and $0.63 billion of COVID-19 testing revenue.Launched a range of high-impact innovative new products including the Gibco CTS TrueCut Cas9 Protein to advance genomic research by delivering consistently higher editing efficiency across a wide range of gene targets and cell types, and the Phadia 2500+ series of instruments launched in the U.S., to provide high throughput testing for both allergy diagnostics and autoimmune diseases. At the American Society for Mass Spectrometry (ASMS) Conference, the company featured new instruments, workflows, software, and industry collaborations enabling customers to generate new analytical insights, enhance productivity, and accelerate next generation vaccine and therapy development.

Want to know how we connect industry leaders with top-level talent? Reach out and learn what we can do for you.

Search Jobs